Insightec has introduced Exablate Prime, the next generation of its magnetic resonance (MR)-guided focused ultrasound system, Exablate Neuro.

Exablate Prime offers enhanced precision, efficiency, and user experience for both surgeons and patients.

It continues to enable incisionless neurosurgery for outpatient procedures, providing relief for individuals with movement disorders such as essential tremors.

The new system features an intuitive user interface that is designed with guided workflows, automated steps, and a streamlined UI.

It also includes intelligent algorithms for one-click skull-density-ratio calculations, automatic fusion, and AC/PC identification, as well as efficient no-pass region detection.

The temperature-driven control is enabled by an accurate temperature prediction algorithm to enhance the therapy delivery precision.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Insightec CEO and board chairman Maurice Ferre said: “Our unwavering commitment to enhancing patient care through innovative technology led us to develop Exablate Prime.

“Although Exablate Neuro has revolutionised the field of neurosurgery, Exablate Prime takes it to entirely new levels, pushing the boundaries of what is possible. We couldn’t be more proud of the end result – Exablate Prime is the future of incisionless neurosurgery.”

Exablate Prime also offers increased specificity and control with sub-millimetric targeting and advanced shaping masks.

Real-time monitoring capabilities include plane thermal spot visualisation and cumulative thermal dose overlays.

Before its launch, Exablate Prime underwent rigorous testing at Rambam Hospital in Haifa, Israel, where feedback was collected and improvements were made.

It was then tested in the US by Oregon Health and Science University, ensuring that the system met the high standards and practical needs of neurosurgeons.

Oregon Health and Sciences University functional neurosurgery director Dr Ahmed Raslan said: “We pride ourselves as trailblazers in healthcare innovation, so we were well prepared to be among the first to test drive Exablate Prime.

“We were pleased with the new interface and efficiency of the system and believe it will significantly and positively impact our neuroscience program – and the lives of those patients we treat – for years to come.”